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A B S T R A C T
The validation of the lipid hypothesis, which pertains to the relationship between dys-
lipidemia and atherogenesis, has established the central role of hypolipidemic treat-
ment in the frontline of primary and secondary prevention of coronary artery disease. 
However, the complexity of the lipoprotein disorders, which are usually associated 
with more than one biochemical abnormalities, and the availability of several hypo-
lipidemic agents in the existing therapeutic armamentarium with combined beneficial 
effects of variable intensity on several lipoproteins, have stressed the need for the 
development and implementation of easily applicable therapeutic algorithms which 
will enable the individualized tailoring of hypolipidemic management with maximal 
efficiency and safety. One such algorithm of individualized tailoring of hypolipidemic 
therapy is being proposed in this brief overview. 
The ultimate target of lipid-lowering therapy is to decrease the risk of coronary 
heart disease. Thus, the priorities in hypolipidemic treatment should be ranked accord-
ing to the existing state of evidence concerning the relationship between cholesterol 
or triglyceride levels and the risk of coronary artery disease (CAD). A plethora of 
data have demonstrated the log-linear relationship between low-density lipoprotein 
cholesterol (LDL-C) levels and coronary heart disease risk in a wide scale of LDL-C 
concentrations [1-4] High-density lipoprotein cholesterol (HDL-C) levels are also 
inversely associated with the presence of CAD, while a randomized trial has demon-
strated that pharmacological interventions targeting low HDL-C levels have a role in 
the secondary prevention of cardiovascular events among patients with low baseline 
HDL cholesterol levels [5] The role of hypertriglyceridemia as a coronary risk factor 
has not been fully elucidated. The correlation between elevated triglyceride levels and 
the risk of CAD is not established in multivariate analyses due to the association of 
hypertriglyceridemia with diabetes, obesity, alcohol consumption and chronic renal 
failure. However, hypertriglyceridemia has been demonstrated to be an independent 
risk factor for CAD in several subgroups of patients including women, diabetics and 
middle-aged and elderly men [6].
T H E R A P E U T I C  L I F E  S T Y L E  C H A N G E S
It is imperative to emphasize the primary role of physical activity, weight control 
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and dietary changes in the management of all subjects with 
an impaired lipid profile. Regular exercise training has been 
shown to increase HDL-C in a dose-dependent manner and 
reduce plasma triglyceride concentrations [7-9]. The adoption 
of a diet low in cholesterol and saturated fat is estimated to 
decrease LDL-C levels by 11 to 15% and probably by even 
20% [10]. Furthermore, weight loss has a beneficial effect on 
HDL and triglyceride levels [11-13]. Thus, therapeutic lifestyle 
changes (TLC) should always be integrated in the lipid-lower-
ing therapeutic strategy and in cases of mild or even moderate 
lipid disorders the abovementioned interventions may suffice 
to reach the target lipid levels.
L O W E R I N G  L D L - C H O L E S T E R O L
The clinical scenarios where lipid lowering treatment is 
needed could be briefly summarized in the following cases 
(1) elevated LDL-C; (2) elevated non-HDL-C in patients with 
high levels of triglycerides (200 to 500 mg/dL); (3) low HDL-C; 
(4) diabetic dyslipidemia; and (5) very high triglycerides. In 
all these clinical situations, the primary goal is to reduce the 
LDL-C plasma concentration to the corresponding target level 
which is determined by the individual’s risk of CAD accord-
ing to the National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III (ATP III) recommendations (Table 
1) [14,15]. The available drugs which primarily lower LDL-C 
are hydroxymethylglutaryl-coenzyme A reductase inhibitors 
(statins), bile acid binding resins, and ezetimibe, a recently 
developed selective inhibitor of intestinal cholesterol absorp-
tion (Table 2) [16]. Among these LDL-C lowering agents the 
drugs of first choice for achievement of LDL-C goal should 
be a member of the statin group largely due to their favour-
able safety profile combined with their demonstrated potency 
in reducing LDL-C and adverse cardiovascular events in 
primary [17,18] and secondary [1-4,19-21] prevention trials. 
When statins can not be used because of patient intolerance 
or contraindications, ezetimibe or bile acid resins should be 
suggested in combination with therapeutic lifestyle changes 
in order to achieve the treatment goal. Bile acid resins and 
ezetimibe are not systemically absorbed and thus can be ad-
ministered in subgroups of patients in whom systemic exposure 
should be rather avoided, such as children, young patients and 
women of childbearing age.
In the majority of cases, a moderate dose of a high efficacy 
statin (rosuvastatin, atorvastatin, simvastatin, and pravastatin 
in order of decreasing potency) is expected to achieve the 
LDL-C goal. However, in patients with highly increased LDL-
C baseline levels, including subjects with heterozygous familial 
hypercholesterolemia and LDL-C levels ranging between 250 
and 400 mg/dL, the therapeutic target would be a decrease in 
mean LDL levels by 50 to 75%, which can not be achieved with 
TABLE 1. LDL-C goals and cutoff levels for initiation of TLC and drug treatment in different risk categories (Adult 
Treatment Panel III guidelines).
Risk Category LDL-C goal Cut-off level for Cut-off level for initiation
  TLC initiation of pharmacological treatment
High risk: CHD* or CHD risk equivalents† <100 mg/dL ≥100 mg/dL ≥100 mg/dL
(10-year risk > 20%) (optional goal: <70 mg/dL)  (<100 mg/dL: consider drug options)
Moderately high risk: 2+ risk factors‡ <130 mg/dL§ ≥130 mg/dL ≥130 mg/dL
(10-year risk 10% to 20%)   (100–129 mg/dL;
   consider drug options)
Moderate risk: 2+ risk factors‡ <130 mg/dL ≥130 mg/dL ≥160 mg/dL
(10-year risk <10%) 
Lower risk: 0–1 risk factor|| <160 mg/dL ≥160 mg/dL ≥190 mg/dL
   (160–189 mg/dL: LDL-lowering 
   drug optional)
* CHD includes history of myocardial infarction, unstable angina, stable angina, coronary artery procedures (angioplasty or bypass surgery), 
or evidence of clinically significant myocardial ischemia.
†CHD risk equivalents include clinical manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic 
aneurysm, and carotid artery disease [transient ischemic attacks or stroke of carotid origin or >50% obstruction of a carotid artery]), diabetes, and 
2+ risk factors with 10-year risk for CHD >20%.
‡ Risk factors include cigarette smoking, hypertension (BP ≥140/90 mmHg or on antihypertensive medication), low HDL cholesterol (<40 mg/dL), 
family history of premature CHD (CHD in male first-degree relative <55 years of age; CHD in female first-degree relative <65 years of age), and 
age (men ≥ 45 years; women ≥55 years).
§ Optional LDL-C goal <100 mg/dL.
|| Almost all people with zero or 1 risk factor have a 10-year risk <10%, and 10-year risk assessment in people with zero or 1 risk factor is thus not 
necessary.
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the administration of moderate doses of statins. Thus, the next 
step would be the administration of either a high efficacy statin 
in the maximal dose or the addition of ezetimibe or a resin 
on top of the already administered moderate dose of statin. 
Among the abovementioned therapeutic alternatives, the first-
choice regimen seems to be the combination of moderate statin 
dose with ezetimibe. The complementary mechanisms of ac-
tion of these different classes of lipid-lowering drugs ensure 
an additive LDL-C lowering of about 18% when ezetimibe is 
added on top of statin [22-24], compared to an average 6% 
incremental LDL-C reduction achieved by every doubling of 
statin dose. It is also of primary importance that the enhanced 
lipid lowering potency offered by the combination of statin 
with ezetimibe is associated with a safety profile similar to 
the moderate-dose statin monotherapy. Furthermore, the 
augmented beneficial effect offered by up-titration of statins 
should be outweighed against a dose-dependent increase in the 
incidence of reversible transaminase elevation and myositis. 
On the other hand though, despite the robust existing data 
regarding the efficacy of the statin-ezetimibe combination in 
reducing LDL-C levels, there are no clinical outcome data 
which may ensure us that the achievement of the LDL-C goal, 
avoiding incremental dosing of statins, will be translated to 
morbidity and mortality benefit. 
In highly demanding patients with CAD and refractory 
hypercholesterolemia or with difficult to treat heterozygous 
or even homozygous familial hypercholesterolemia [25], the 
combination of moderate statin dose with ezetimibe may prove 
inadequate to attain the indicated LDL goal. In these cases 
the next step should be the administration of maximal dose of 
a high-efficacy statin with ezetimibe or even a triple therapy 
consisting of maximal statin dose, ezetimibe and resin. 
TABLE 2. Mechanism of action, dose range, major lipid effects and adverse effects of lipid-lowering medications 
Agents Mechanism of action Dose range Major effects on lipid levels Major adverse effects
Statins (HydroxyMethylGlutaryl-Coenzyme A reductase inhibitors)
Rosuvastatin Inhibition of the rate limiting   10-40 mg 10 mg â LDL 45%*† Reversible elevation in
Atorvastatin step of cholesterol synthesis  10-80 mg 10 mg â LDL 39%*† transaminases and myositis
Simvastatin resulting in á expression of  10-80 mg 20 mg â LDL 35%*†
Fluvastatin LDL receptors, â hepatic  20-80 mg 40 mg â LDL 25%*†
Lovastatin production of LDL, VLDL  20-80 mg 40 mg â LDL 31%*†
Pravastatin and á LDL-C plasma clearance 10-40 mg 40 mg â LDL 34%*†
Cholesterol absorption inhibitor
Ezetimibe  Interference with the intestinal  10 mg 10 mg â LDL 18% Few side effects (similar 
 cholesterol transporter Niemann    adverse effect profile 
 Pick C1-like1 protein 1   with placebo)
Bile acid binding resins
Cholestyramine Inhibition of bile 2-24 gr â LDL 10-30% in a dose Gastrointestinal intolerance
Colestipol acid reabsorption 5-30 gr dependent manner 
Fibrates
Gemfibrozil Interaction with  600-1200 mg 1200 mg áHDL 6%, Dyspepsia, gallstones,
 transcription factor   âTG 31% [5] átransaminases,
Fenofibrate PPARá regulating  200 mg 200 mg áHDL 5%, interaction with
 transcription of LPL,    â TG 29% [37] anticoagulants, myopathy
Bezafibrate apoCII and apoB genes 400 mg 400 mg áHDL 18%,
   â TG 21% [30]
Niacin
Nicotinic acid Decreased hepatic  1-3 gr â TG 20-50%,  Skin flushing, hyperglycemia,
 secretion of VLDL and   á HDL 15-35%, from the periphery
 decreased FFA mobilization  â LDL 5-25% hyperuricemia, 
    hepatotoxicity, gastritis
Omega-3 fatty acids
Omega-3 fatty Decreased VLDL synthesis 3-5 gr â TG 25-30%, á HDL 1-3%, Gastrointestinal disturbances
acids   â LDL 5-10%
* Estimated LDL reductions were obtained from US FDA package inserts for each drug.
† For every doubling of the mentioned dose, an approximate 6% additional decrease in LDL-C level can be achieved.
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I N C R E A S E D  T R I G L Y C E R I D E  L E V E L S
The management of patients with increased triglyceride 
levels should be addressed under the scope of the general 
rule that LDL-C levels represent the primary therapeutic 
target. Once the respective LDL-C goal has been achieved, 
non-HDL levels (non-HDL-C = TC – HDL-C = VLDL-C 
+ LDL-C, the latter including IDL), which include all cho-
lesterol carrying particles except HDL-C, should represent 
the secondary goal and the target value should be 30 mg/dL 
higher than the respective LDL-C goal. The two classes of 
hypolipidemic agents which have an established role in the 
treatment of patients with increased triglyceride and/or non-
HDL levels are nicotinic acid derivatives and fibrates (Table 
2). The major limitation of these agents is their adverse effect 
profile which necessitates the maintenance of a heightened 
vigilance, especially in cases of statin and fibrate co-admin-
istration in patients with combined dyslipidemias where both 
LDL-C and non-HDL-C goals should be achieved. Whenever 
this combination is indicated, fenofibrate should be preferred 
instead of gemfibrozil or bezafibrate, since fenofibrate does 
not interfere with statin glucorinidation and thus does not 
substantially increase the risk of myopathy [26]. Fish oil de-
rived omega-3 fatty acids (eicosapentaenoic acid, C20:5n-3 
[EPA] and docosa-hexaenoic acid, C22:6n-3 [DHA]) have 
also a therapeutic role in the management of patients with 
hypertriglyceridemia. Doses of omega-3 fatty acids exceed-
ing 3 grams daily, which can only be obtained by consistent 
supplementation and not by diet, exhibit a triglyceride lowering 
effect by about 25 to 30%, but also exert an LDL increasing 
effect by 5-10% [27].
T H E  R O L E  O F  H D L - C H O L E S T E R O L
Accumulating data further validating the role of HDL-
C as a CAD risk factor have provided a sufficient state of 
evidence for the NCEP-ATPIII to define HDL-C levels as 
the tertiary goal of hypolipidemic treatment. The American 
Heart Association has recently redefined low HDL-C levels 
as <40 mg/dL for men and <50 mg/dL for women [28] and 
the American Diabetes Association has adopted these cut-
off levels as the HDL-C goal for diabetic patients [29]. When 
dietary changes, weight loss and exercise training have proven 
inadequate to achieve the abovementioned HDL goals, phar-
macologic treatment should be instituted. Despite the fact that 
statins have a modest efficacy in increasing HDL levels, their 
administration for treatment of patients with increased LDL-
C levels, in terms of targeting the primary LDL goal, might 
prove adequate in combination with TLC to reach the target 
HDL levels. Among statins, rosuvastatin has been shown to 
exert a slightly more potent effect on HDL-C in comparison to 
atorvastatin, simvastatin and pravastatin [30]. In patients with 
combined dyslipidemia, who maintain decreased HDL levels 
despite the achievement of LDL and non-HDL target levels 
with statin monotherapy or statin plus ezetimibe, the addition 
of niacin or fenofibrate is indicated. It should be highlighted 
that despite the initial concerns regarding the administration 
of niacin in diabetics due to the exerted hyperglycemia, recent 
trials have demonstrated the safe feasibility of this regimen 
with the prerequisite of glucose monitoring and proper adjust-
ment of antidiabetic agents [31,32]. The addition of fenofibrate 
in the hypolipidemic regimen of patients with mixed hyper-
lipidemias might result to an increase of LDL-C, which albeit 
paradoxical, is attributed to the augmenting effect of fibrates 
on lipoprotein lipase activity. In patients with isolated low 
HDL cholesterol, niacin is the agent of choice. The common 
and limiting side effect of flushing is considered to be pros-
taglandin mediated and thus can be mitigated by concurrent 
use of low aspirin dose. 
Recently, a new class of hypolipidemic drugs, cholesterol 
ester transfer protein (CETP) inhibitors, which raise HDL 
cholesterol and lower LDL cholesterol, has been developed, 
but are still used in trial settings only. HDL mimetic agents are 
another group of agents that offer much promise. CETP is a 
plasma glycoprotein that facilitates the transfer of cholesteryl 
esters from HDL-C to Apo-B containing lipoproteins. Torce-
trapib, a CETP inhibitor, has been shown to be effective, safe 
and well tolerated when used in combination with atorvastatin 
therapy [33]. Torcetrapib has been shown to increase HDL 
cholesterol levels by 46% when given alone and by 61% when 
given in combination with atorvastatin, as well as to decrease 
LDL cholesterol levels by more than that achieved by atorvas-
tatin alone. Future trials evaluating the efficacy and safety of 
such drugs remain to establish whether these new therapeutic 
FIGURE 1. Basic principles of lipid lowering management 
based on NCEP-ATP III defined treatment goals.
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agents will reduce the risk for atherosclerosis. 
L I P I D  L O W E R I N G  I N  D I A B E T I C S
Diabetics represent a subgroup of patients with high preva-
lence of combined dyslipidemia usually consisting of slightly 
increased LDL-C levels, small LDL particles, increased tri-
glycerides and decreased HDL-C levels. The lipid-lowering 
management of diabetic patients with an adverse lipid profile 
should not divert from the general rule that “LDL-C comes 
first”, using statins as a first-line agent since their adminis-
tration has been associated with significant reduction in car-
diovascular events among diabetics [19,20,34,35]. However, 
a significant proportion of diabetics who have succeeded 
their primary LDL-C goal, still have low HDL-C, raised tri-
glycerides, and small LDL particles. In order to achieve the 
secondary and tertiary goals of lipid-lowering treatment, either 
niacin or fenofibrate, the only member of the fibrate class that 
can be co-administered with statins with relative safety, can 
be selected. However, the rather disappointing results of the 
FIELD study, whereby fenofibrate failed to demonstrate a 
significant reduction of the primary endpoint versus placebo 
in diabetic patients, combined with a nonsignificant increase 
in cardiac mortality and a modest increase in HDL by 5%, 
further established the role of statins as first choice agents 
in diabetic dyslipidemia, while raised concern regarding the 
additive benefit of fenofibrate administration on top of statins 
in diabetics [36]. It would thus be prudent to suggest the use 
of niacin on top of statins in diabetic patients with decreased 
HDL levels, limiting the use of fenofibrate in diabetics with 
increased triglycerides or those who can not tolerate niacin. 
C O N C L U S I O N
In conclusion, lowering of LDL cholesterol levels to the 
NCEP-ATPIII treatment goals should be set as top priority 
in the management of dyslipidemic patients, while the attain-
ment of non-HDL and HDL target levels respectively repre-
sent the secondary and tertiary goal. The implementation of 
treatment algorithms defined on the basis of achieving the 
abovementioned goals is expected to enhance our efficiency 
in tackling dyslipidemia, thus paving the way towards cardio-
vascular disease prevention. 
R E F E R E N C E S  
 1. Heart Protection Study Collaborative Group. MRC/BHF 
Heart Protection Study of cholesterol lowering with simvas-
tatin in 20,536 high-risk individuals: a randomised placebo-
controlled trial. Lancet 2002; 360(9326):7-22.
 2. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, et al. Pravas-
tatin in elderly individuals at risk of vascular disease (PROS-
PER): a randomised controlled trial. PROspective Study of 
Pravastatin in the Elderly at Risk. Lancet 2002; 360:1623-
1630.
 3. Sever PS, Dahlof B, Poulter NR, Wedel H, et al. Prevention of 
coronary and stroke events with atorvastatin in hypertensive 
patients who have average or lower-than-average cholesterol 
concentrations, in the Anglo-Scandinavian Cardiac Outcomes 
Trial– Lipid Lowering Arm (ASCOT-LLA): a multicentre ran-
domised controlled trial. Lancet 2003; 361:1149-1158.
 4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, et al. In-
tensive versus moderate lipid lowering with statins after acute 
coronary syndromes. N Engl J Med 2004; 350:1495-1504.
 5. Rubins HB, Robins SJ, Collins D, Fye CL, et al. Gemfibrozil 
for the secondary prevention of coronary heart disease in men 
with low levels of high-density lipoprotein cholesterol. Veterans 
Affairs High-Density Lipoprotein Cholesterol Intervention 
Trial Study Group. N Engl J Med 1999; 341:410-418.
 6. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride 
concentration and ischemic heart disease: an eight-year follow-
up in the Copenhagen Male Study. Circulation 1998; 97(11):
1029-36.
 7. Durstine JL, Grandjean PW, Cox CA, Thompson PD. Lipids, 
lipoproteins, and exercise. J Cardiopulm Rehabil 2002; 22:385-
398. 
 8. Thompson PD, Yurgalevitch SM, Flynn MM, Zmuda JM, et 
al. Effect of prolonged exercise training without weight loss 
on high-density lipoprotein metabolism in overweight men. 
Metabolism 1997; 46:217-223.
 9. Durstine JL, Thompson PD. Exercise in the treatment of lipid 
disorders. Cardiol Clin 2001; 19:471-488.
 10. Fletcher B, Berra K, Ades P, Braun LT, et al. Managing abnor-
mal blood lipids: a collaborative approach. Circulation 2005; 
112(20):3184-209.
 11. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: im-
pact on cardiovascular disease. Circulation 1998; 98:1472-1476.
 12. Yu-Poth S, Zhao G, Etherton T, Naglak M, et al. Effects of the 
National Cholesterol Education Program’s Step I and Step II 
dietary intervention programs on cardiovascular disease risk 
factors: a meta-analysis. Am J Clin Nutr 1999; 69:632-646.
 13. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on 
blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 
1992; 56:320–328.
 14. National Cholesterol Education Program (NCEP) Expert Pa-
nel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III). Third Re-
port of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III): final 
report. Circulation 2002; 106:3143–3421.
 15. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, et al. Im-
plications of recent clinical trials for the National Cholesterol 
Education Program Adult Treatment Panel III guidelines. 
Circulation 2004; 110:227–239.
220
HOSPITAL CHRONICLES, SUPPLEMENT 2006
 16. Sudhop T, Lütjohann D, Kodal A, Igel M, et al. Inhibition of 
intestinal cholesterol absortion by ezetimibe in humans. Circu-
lation 2002; 106:1943–8.
 17. Downs JR, Clearfield M, Weis S, Whitney E, et al. Primary 
prevention of acute coronary events with lovastatin in men and 
women with average cholesterol levels: results of AFCAPS/
TexCAPS. Air Force/Texas Coronary Atherosclerosis Preven-
tion Study. JAMA 1998; 279:1615-22.
 18. Shepherd J, Cobbe SM, Ford I, Isles CG, et al. Prevention of 
coronary heart disease with pravastatin in men with hyper-
cholesterolemia. West of Scotland Coronary Prevention Study 
Group. N Engl J Med 1995; 333:1301-7.
 19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, et al. The effect 
of pravastatin on coronary events after myocardial infarction in 
patients with average cholesterol levels. Cholesterol and Recur-
rent Events Trial investigators. N Engl J Med 1996; 335:1001-9.
 20. Prevention of cardiovascular events and death with pravastatin 
in patients with coronary heart disease and a broad range of 
initial cholesterol levels. The Long-Term Intervention with Pra-
vastatin in Ischaemic Disease (LIPID) Study Group. N Engl J 
Med 1998; 339:1349-57.
 21. Randomised trial of cholesterol lowering in 4444 patients with 
coronary heart disease: the Scandinavian Simvastatin Survival 
Study (4S). Lancet 1994; 344:1383-9.
 22. Ballantyne CM. Ezetimibe: efficacy and safety in clinical trials. 
Eur Heart J Supplements 2002; 4(Suppl J):J9–J18.
 23. Gagne C, Bays HE, Weiss SR, Mata P, et al. Efficacy and safety 
of ezetimibe added to ongoing statin therapy for treatment of 
patients with primary hypercholesterolemia. Am J Cardiol 
2002; 90:1084–1091.
 24. Davidson MH, McGarry T, Bettis R, Melani L, et al. Ezeti-
mibe coadministered with simvastatin in patients with primary 
hypercholesterolemia. J Am Coll Cardiol 2002; 40:2125–2534.
 25. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of eze-
timibe coadministered with atorvastatin or simvastatin in 
patients with homozygous familial hypercholesterolemia. Cir-
culation 2002; 105:2469–2475.
 26. Pan WJ, Gustavson LE, Achari R, Rieser MJ, et al. Lack of 
a clinically significant pharmacokinetic interaction between 
fenofibrate and pravastatin in healthy volunteers. J Clin Phar-
macol 2000; 40:316–323.
 27. Harris WS. n-3 Fatty acids and serum lipoproteins: human 
studies. Am J Clin Nutr 1997; 65(5 Suppl):1645S–1654S.
 28. Mosca L, Appel LJ, Benjamin EJ, Berra K, et al. Evidence-
based guidelines for cardiovascular disease prevention in 
women. Circulation 2004; 109:672– 693.
 29. American Diabetes Association. Dyslipidemia management 
in adults with diabetes. Diabetes Care 2004; 27(suppl 1):S68 
–S71.
 30. Jones PH, Davidson MH, Stein EA, Bays HE, et al. Compari-
son of the efficacy and safety of rosuvastatin versus atorvas-
tatin, simvastatin, and pravastatin across doses (STELLAR 
trial). Am J Cardiol 2003; 92:152-160.
 31. Elam MB, Hunninghake DB, Davis KB, Garg R, et al. Effect 
of niacin on lipid and lipoprotein levels and glycemic control in 
patients with diabetes and peripheral arterial disease. The AD-
MIT study: a randomized trial. JAMA 2000; 284:1263-1270.
 32. Grundy SM, Vega GL, McGovern ME, Tulloch BR, et al. Ef-
ficacy, safety, and tolerability of once-daily niacin for the treat-
ment of dyslipidemia associated with type 2 diabetes: results of 
the Assessment of Diabetes Control and Evaluation of the Ef-
ficacy of Niaspan Trial. Arch Intern Med 2002; 162:1568 –1576. 
 33. Zareba G. Torcetrapid and atorvastatin: a novel combination 
therapy for dyslipidemia. Drugs Today (Barc) 2006; 42:95-102.
 34. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, et al. Cho-
lesterol lowering with simvastatin improves prognosis of dia-
betic patients with coronary heart disease: a subgroup analysis 
of the Scandinavian Simvastatin Survival Study (4S). Diabetes 
Care 1997; 20:614-620.
 35. Heart Protection Study Collaborative Group: MRC/BHF 
Heart Protection Study of cholesterol-lowering with simvas-
tatin in 5963 people with diabetes: a randomised placebo-con-
trolled trial. Lancet 2003; 361:2005–2016.
 36. Keech A, Simes RJ, Barter P, Best J, et al. Effects of long-term 
fenofibrate therapy on cardiovascular events in 9795 people 
with type 2 diabetes mellitus (the FIELD study): randomised 
controlled trial. Lancet 2005; 366:1849-61.
 37. BIP Study Group. Secondary prevention by raising HDL cho-
lesterol and reducing triglycerides in patients with coronary 
artery disease: the Bezafibrate Infarction Prevention (BIP) 
study. Circulation 2000; 102:21–27.
